MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Withdrawn Drug Compound Library

MCE 站：Withdrawn Drug Compound Library

Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial ａnd regulatory problems ａnd other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance ａnd other costs to develop the drug. Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, ａnd in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications. MCE has sorted out 186 drug compounds withdrawn from the market through FDA, EMA ａnd other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms ａnd discovering new indications of drugs.

Description & Advantages:

    A unique collection of 186 Withdrawn Drug compounds for high throughput screening (HTS) ａnd high content screening (HCS).

    A useful tool for conducting research on drug side effects or drug toxicity mechanisms ａnd discovering new indications of drugs.

   Target diverse, medicinally active ａnd cell permeable.

   More detailed compound information with structure, IC50, ａnd other chemical & biological data.

   High purity ａnd quality validated by NMR ａnd LC/MS.

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   40,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。